By Denny Jacob
Keros Therapeutics' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events.
Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year.
The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy.
Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 12, 2024 07:38 ET (12:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。